Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design

Jozef Bartunek, Beth Davison, Warren Sherman, Thomas Povsic, Timothy D. Henry, Bernard Gersh, Marco Metra, Gerasimos Filippatos, Roger Hajjar, Atta Behfar, Christian Homsy, Gad Cotter, William Wijns, Michal Tendera, Andre Terzic

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Aims Cardiopoiesis is a conditioning programme that aims to upgrade the cardioregenerative aptitude of patient-derived stem cells through lineage specification. Cardiopoietic stem cells tested initially for feasibility and safety exhibited signs of clinical benefit in patients with ischaemic heart failure (HF) warranting definitive evaluation. Accordingly, CHART-1 is designed as a large randomized, sham-controlled multicentre study aimed to validate cardiopoietic stem cell therapy. Methods Patients (n = 240) with chronic HF secondary to ischaemic heart disease, reduced LVEF (6 bone marrow-derived and lineage-directed autologous cardiopoietic stem cells administered via a retention-enhanced intramyocardial injection catheter or a sham procedure. The primary efficacy endpoint is a hierarchical composite of mortality, worsening HF, Minnesota Living with Heart Failure Questionnaire score, 6 min walk test, LV end-systolic volume, and LVEF at 9 months. The secondary efficacy endpoint is the time to cardiovascular death or worsening HF at 12 months. Safety endpoints include mortality, readmissions, aborted sudden deaths, and serious adverse events at 12 and 24 months. Conclusion The CHART-1 clinical trial is powered to examine the therapeutic impact of lineage-directed stem cells as a strategy to achieve cardiac regeneration in HF populations. On completion, CHART-1 will offer a definitive evaluation of the efficacy and safety of cardiopoietic stem cells in the treatment of chronic ischaemic HF. Trial registration: NCT01768702

Original languageEnglish (US)
Pages (from-to)160-168
Number of pages9
JournalEuropean Journal of Heart Failure
Volume18
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Heart Failure
Stem Cells
Safety
Therapeutics
Mortality
Cell Lineage
Cell- and Tissue-Based Therapy
Sudden Death
Multicenter Studies
Myocardial Ischemia
Regeneration
Catheters
Bone Marrow
Clinical Trials
Injections
Population

Keywords

  • Cardiopoiesis
  • Heart failure
  • Ischaemic cardiomyopathy
  • Regenerative medicine
  • Stem cell

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. / Bartunek, Jozef; Davison, Beth; Sherman, Warren; Povsic, Thomas; Henry, Timothy D.; Gersh, Bernard; Metra, Marco; Filippatos, Gerasimos; Hajjar, Roger; Behfar, Atta; Homsy, Christian; Cotter, Gad; Wijns, William; Tendera, Michal; Terzic, Andre.

In: European Journal of Heart Failure, Vol. 18, No. 2, 01.02.2016, p. 160-168.

Research output: Contribution to journalArticle

Bartunek, J, Davison, B, Sherman, W, Povsic, T, Henry, TD, Gersh, B, Metra, M, Filippatos, G, Hajjar, R, Behfar, A, Homsy, C, Cotter, G, Wijns, W, Tendera, M & Terzic, A 2016, 'Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design', European Journal of Heart Failure, vol. 18, no. 2, pp. 160-168. https://doi.org/10.1002/ejhf.434
Bartunek J, Davison B, Sherman W, Povsic T, Henry TD, Gersh B et al. Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. European Journal of Heart Failure. 2016 Feb 1;18(2):160-168. https://doi.org/10.1002/ejhf.434
Bartunek, Jozef ; Davison, Beth ; Sherman, Warren ; Povsic, Thomas ; Henry, Timothy D. ; Gersh, Bernard ; Metra, Marco ; Filippatos, Gerasimos ; Hajjar, Roger ; Behfar, Atta ; Homsy, Christian ; Cotter, Gad ; Wijns, William ; Tendera, Michal ; Terzic, Andre. / Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. In: European Journal of Heart Failure. 2016 ; Vol. 18, No. 2. pp. 160-168.
@article{1be9f406c1d04c3096d1c7d46433b9b7,
title = "Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design",
abstract = "Aims Cardiopoiesis is a conditioning programme that aims to upgrade the cardioregenerative aptitude of patient-derived stem cells through lineage specification. Cardiopoietic stem cells tested initially for feasibility and safety exhibited signs of clinical benefit in patients with ischaemic heart failure (HF) warranting definitive evaluation. Accordingly, CHART-1 is designed as a large randomized, sham-controlled multicentre study aimed to validate cardiopoietic stem cell therapy. Methods Patients (n = 240) with chronic HF secondary to ischaemic heart disease, reduced LVEF (6 bone marrow-derived and lineage-directed autologous cardiopoietic stem cells administered via a retention-enhanced intramyocardial injection catheter or a sham procedure. The primary efficacy endpoint is a hierarchical composite of mortality, worsening HF, Minnesota Living with Heart Failure Questionnaire score, 6 min walk test, LV end-systolic volume, and LVEF at 9 months. The secondary efficacy endpoint is the time to cardiovascular death or worsening HF at 12 months. Safety endpoints include mortality, readmissions, aborted sudden deaths, and serious adverse events at 12 and 24 months. Conclusion The CHART-1 clinical trial is powered to examine the therapeutic impact of lineage-directed stem cells as a strategy to achieve cardiac regeneration in HF populations. On completion, CHART-1 will offer a definitive evaluation of the efficacy and safety of cardiopoietic stem cells in the treatment of chronic ischaemic HF. Trial registration: NCT01768702",
keywords = "Cardiopoiesis, Heart failure, Ischaemic cardiomyopathy, Regenerative medicine, Stem cell",
author = "Jozef Bartunek and Beth Davison and Warren Sherman and Thomas Povsic and Henry, {Timothy D.} and Bernard Gersh and Marco Metra and Gerasimos Filippatos and Roger Hajjar and Atta Behfar and Christian Homsy and Gad Cotter and William Wijns and Michal Tendera and Andre Terzic",
year = "2016",
month = "2",
day = "1",
doi = "10.1002/ejhf.434",
language = "English (US)",
volume = "18",
pages = "160--168",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design

AU - Bartunek, Jozef

AU - Davison, Beth

AU - Sherman, Warren

AU - Povsic, Thomas

AU - Henry, Timothy D.

AU - Gersh, Bernard

AU - Metra, Marco

AU - Filippatos, Gerasimos

AU - Hajjar, Roger

AU - Behfar, Atta

AU - Homsy, Christian

AU - Cotter, Gad

AU - Wijns, William

AU - Tendera, Michal

AU - Terzic, Andre

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Aims Cardiopoiesis is a conditioning programme that aims to upgrade the cardioregenerative aptitude of patient-derived stem cells through lineage specification. Cardiopoietic stem cells tested initially for feasibility and safety exhibited signs of clinical benefit in patients with ischaemic heart failure (HF) warranting definitive evaluation. Accordingly, CHART-1 is designed as a large randomized, sham-controlled multicentre study aimed to validate cardiopoietic stem cell therapy. Methods Patients (n = 240) with chronic HF secondary to ischaemic heart disease, reduced LVEF (6 bone marrow-derived and lineage-directed autologous cardiopoietic stem cells administered via a retention-enhanced intramyocardial injection catheter or a sham procedure. The primary efficacy endpoint is a hierarchical composite of mortality, worsening HF, Minnesota Living with Heart Failure Questionnaire score, 6 min walk test, LV end-systolic volume, and LVEF at 9 months. The secondary efficacy endpoint is the time to cardiovascular death or worsening HF at 12 months. Safety endpoints include mortality, readmissions, aborted sudden deaths, and serious adverse events at 12 and 24 months. Conclusion The CHART-1 clinical trial is powered to examine the therapeutic impact of lineage-directed stem cells as a strategy to achieve cardiac regeneration in HF populations. On completion, CHART-1 will offer a definitive evaluation of the efficacy and safety of cardiopoietic stem cells in the treatment of chronic ischaemic HF. Trial registration: NCT01768702

AB - Aims Cardiopoiesis is a conditioning programme that aims to upgrade the cardioregenerative aptitude of patient-derived stem cells through lineage specification. Cardiopoietic stem cells tested initially for feasibility and safety exhibited signs of clinical benefit in patients with ischaemic heart failure (HF) warranting definitive evaluation. Accordingly, CHART-1 is designed as a large randomized, sham-controlled multicentre study aimed to validate cardiopoietic stem cell therapy. Methods Patients (n = 240) with chronic HF secondary to ischaemic heart disease, reduced LVEF (6 bone marrow-derived and lineage-directed autologous cardiopoietic stem cells administered via a retention-enhanced intramyocardial injection catheter or a sham procedure. The primary efficacy endpoint is a hierarchical composite of mortality, worsening HF, Minnesota Living with Heart Failure Questionnaire score, 6 min walk test, LV end-systolic volume, and LVEF at 9 months. The secondary efficacy endpoint is the time to cardiovascular death or worsening HF at 12 months. Safety endpoints include mortality, readmissions, aborted sudden deaths, and serious adverse events at 12 and 24 months. Conclusion The CHART-1 clinical trial is powered to examine the therapeutic impact of lineage-directed stem cells as a strategy to achieve cardiac regeneration in HF populations. On completion, CHART-1 will offer a definitive evaluation of the efficacy and safety of cardiopoietic stem cells in the treatment of chronic ischaemic HF. Trial registration: NCT01768702

KW - Cardiopoiesis

KW - Heart failure

KW - Ischaemic cardiomyopathy

KW - Regenerative medicine

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=84958123357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958123357&partnerID=8YFLogxK

U2 - 10.1002/ejhf.434

DO - 10.1002/ejhf.434

M3 - Article

C2 - 26662998

AN - SCOPUS:84958123357

VL - 18

SP - 160

EP - 168

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 2

ER -